Skip to main content
. 2023 Jan 20;33:101430. doi: 10.1016/j.bbrep.2023.101430

Fig. 4.

Fig. 4

Determination of the effect of the combined treatments of AZD5363+AZD8542+CCR or AZD8542+CCR+RV against GBM recurrence. (A) Graphs show survival (as percentage) of U-87 MG (upper panel) and A172 (lower panel), cell lines incubated with AZD5363+AZD8542+CCR or AZD8542+CCR+RV for 24 h, 48 h and 72 h; cell viability was determined by MTT. (B) Left panel shows a representative image of EdU positive cells, U-87 MG (upper panel) and A172 (lower panel) cells, bar 40 μm. Green cells, are EdU positive cells, arrows, indicate positive cells treated with AZD5363+AZD8542+CCR or AZD8542+CCR+RV. Right panel shows the percentage of EdU positive cell ratio, U-87 MG (left panel) and A172 (right panel) cell lines. Data obtained from three fields per experimental condition, of three independent experiments. Percentage of positive EdU cells was obtained: EdU+/DAPI+ * 100%. (C) A representative image showing U-87 MG gliomaspheres (left panel) and A172 gliomaspheres (right panel). Graphs, shows the survival of U-87 MG cells, derived gliomaspheres (as percentage) and of A172 cells derived gliomaspheres (as percentage), treated with AZD5363+AZD8542+CCR and AZD8542+CCR+RV for 72 h. One-way ANOVA, followed by Tukey; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, non-significant. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)